Compare Biogen Inc (BIIB) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Fortinet Inc — how do they compare? Biogen Inc trades at $191.1 (market cap $28.34B), while Fortinet Inc trades at $168.41 (market cap $122.23B). The key difference: Fortinet Inc is far larger — about 4.3× Biogen Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | FTNT | |
|---|---|---|
Market Cap | $28.34B | $122.23B |
Sector | Health | Technology |
52-Week High | $216.63 | $166.83 |
52-Week Low | $122.68 | $74.39 |
Enterprise Value | $30.62B | $119.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Fortinet (FTNT) trades at $160.62, up 1.97% on the day, with strong technical momentum and bullish moving averages. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.82 exceeding the $0.619 estimate. Revenue growth remains solid, reaching $6.80B in 2025, while high valuation ratios like a P/E of 62.26 reflect premium investor expectations. Recent news highlights expansion in AI-driven security solutions, positioning FTNT to capitalize on rising cybersecurity demand.
The outlook for FTNT is positive, driven by sustained demand for cybersecurity and AI integration, though elevated valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, but the average price target of $121.11 suggests caution relative to the current price. Investors should monitor execution against raised 2026 guidance and industry spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
